Becton Dickinson & Co. closed 3.20% below its 52-week high of $248.42, which the company achieved on March 28th.

Becton, Dickinson and Company and Biosero, a developer of laboratory automation solutions to orchestrate scientific discoveries, announced a ...

In a recent transaction, Shan David, Executive Vice President and Chief ISC Officer at Becton Dickinson & Co (NYSE:BDX), sold ...

(This Jan. 21 story has been corrected to fix the share price gain to 57% from 45% in paragraph 6) (Reuters) - Masimo named Becton Dickinson executive Katie Szyman as its top boss, the medical device ...

Paoletti, a charge nurse at Jefferson Torresdale Hospital, reported the problem internally, through the health system’s Great ...

Barclays analyst Matt Miksic lowered the firm’s price target on Becton Dickinson (BDX) to $278 from $312 and keeps an Overweight rating on the ...

Becton, Dickinson and Co. (BD) is investing in its U.S. manufacturing network to add capacity for critical medical devices, ...

Shares of Becton Dickinson & Co. BDX shed 1.02% to $237.92 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.61% to 6,086 ...

The new versions of BD flow cytometer instrument software compatible with Biosero automation software for the BD FACSymphony A1™ Cell Analyzer, BD FACSymphony™ A5 SE Cell Anal ...

Gateway Investment Advisers LLC reduced its position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark Global Fund” fourth quarter 2024 investor letter. A copy ...

Becton Dickinson's (NYSE:BDX) stock is up by 4.3% over the past month. As most would know, long-term fundamentals ...